» Articles » PMID: 23972645

Favorable Acceptance of Mini-tablets Compared with Syrup: a Randomized Controlled Trial in Infants and Preschool Children

Overview
Journal J Pediatr
Specialty Pediatrics
Date 2013 Aug 27
PMID 23972645
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate acceptability of 2 mm solid dosage forms (mini-tablets) as an alternative administration modality in young children in comparison with syrup.

Study Design: Three hundred six pediatric in- and outpatients aged 6 months-5 years (51 in each of 6 age groups) were recruited. An open, randomized cross-over study was conducted to compare acceptability and capability to swallow 2 mm uncoated or coated mini-tablets vs 3 mL syrup.

Results: In the overall patient population of 306 children, the acceptability of uncoated mini-tablets was superior to syrup (difference in proportions 14.8%, 95% CI 10.2-19.4; P < .0001). In line with this finding, the level of capability to swallow was higher for uncoated mini-tablets compared with syrup as well (difference in proportions 12.3%, 95% CI 5.4-19.3; P = .0008). All 3 pharmaceutical formulations were well tolerated, and none of the 306 children inhaled or coughed because of the syrup or the uncoated mini-tablet; only 2 of the 306 children (both in age group 0.5-1 year) coughed because of the coated mini-tablet, in both cases without clinical relevance.

Conclusions: Mini-tablets are a valuable alternative to syrup for children 6 months-6 years of age and are more acceptable compared with liquid formulation. Regulatory bodies such as Food and Drug Administration and European Medicine Agency are encouraged to take our data into account for guideline updates and future drug approval processes.

Citing Articles

Development and Characterization of Niaprazine-Loaded Xanthan Gum-Based Gel for Oral Administration.

Giuliano E, Longo E, Gagliardi A, Costa S, Squillace F, Voci S Gels. 2025; 11(2).

PMID: 39996644 PMC: 11854669. DOI: 10.3390/gels11020101.


Acceptability and Palatability of Novel Orodispersible Minitablets of Enalapril in Children up to the Age of 6 with Heart Failure.

Lazic M, Djukic M, Vukomanovic V, Bijelic M, Obarcanin E, Bajcetic M J Clin Med. 2025; 14(3).

PMID: 39941586 PMC: 11818611. DOI: 10.3390/jcm14030915.


Development and Characterization of Trihexyphenidyl Orodispersible Minitablets: A Challenge to Fill the Therapeutic Gap in Neuropediatrics.

Olivera C, Boscolo O, Dobrecky C, Ortega C, Favier L, Cianchino V Pharmaceutics. 2025; 17(1).

PMID: 39861657 PMC: 11769368. DOI: 10.3390/pharmaceutics17010005.


Application of Hydrophilic Polymers to the Preparation of Prolonged-Release Minitablets with Bromhexine Hydrochloride and Bisoprolol Fumarate.

Grzejdziak A, Brniak W, Lengier O, Zarek J, Hliabovich D, Mendyk A Pharmaceutics. 2024; 16(9).

PMID: 39339190 PMC: 11434728. DOI: 10.3390/pharmaceutics16091153.


Ambroxol hydrochloride spray (Luo Runchang®) in the treatment of acute respiratory infectious diseases: a prospective, multicenter, open label, randomized controlled study.

Cheng L, Liu M, Wang R, Cao S, Li R, Su B Front Pediatr. 2024; 12:1380189.

PMID: 39301037 PMC: 11410591. DOI: 10.3389/fped.2024.1380189.